BEAM broke above its upper Bollinger Band on September 06, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 28 similar instances where the stock broke above the upper band. In of the 28 cases the stock fell afterwards. This puts the odds of success at .
The Momentum Indicator moved below the 0 level on September 21, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAM as a result. In of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BEAM entered a downward trend on September 05, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BEAM's RSI Oscillator exited the oversold zone, of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on August 28, 2023. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.319) is normal, around the industry mean (22.634). P/E Ratio (0.000) is within average values for comparable stocks, (131.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.085). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (21.459) is also within normal values, averaging (305.056).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FMCRX | 15.49 | -0.02 | -0.13% |
Federated Hermes Mid-Cap Index IS | |||
DQIRX | 24.46 | -0.04 | -0.16% |
BNY Mellon Equity Income Fund I | |||
RIREX | 62.25 | -0.10 | -0.16% |
American Funds Capital Income Bldr R4 | |||
DFVIX | 16.75 | -0.03 | -0.18% |
DFA International Value III | |||
MIGPX | 8.81 | -0.02 | -0.23% |
Morgan Stanley Inst Global Insgt A |
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
---|---|---|---|---|
BEAM | 100% | -4.81% | ||
CRSP - BEAM | 76% Closely correlated | -1.24% | ||
NTLA - BEAM | 75% Closely correlated | -3.40% | ||
VERV - BEAM | 71% Closely correlated | -2.89% | ||
EDIT - BEAM | 69% Closely correlated | -1.88% | ||
DNLI - BEAM | 66% Closely correlated | -1.51% | ||
More |